FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C	20549
-----------------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Alpern Robert J						2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ABBV]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Alpeni Robert J															X	Direc	ctor		10% C	wner		
(Last) (First) (Middle) 1 N. WAUKEGAN ROAD					3. Date of Earliest Transaction (Month/Day/Year) 05/09/2014											Offic belov	er (give title w)		Other below)	(specify		
(Street) NORTH CHICAGO IL 60064			4. If Amendment, Date of Original Filed (Month/Day/Year)										Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person									
(City)	(St	ate) (Zip)																			
		Tabl	e I - Nor	n-Deriv	ative	Se	curitie	s Acc	quired,	Dis	posed o	f, or	Bene	eficia	ılly (Owne	ed					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr. 5)		ities Acquired (A d Of (D) (Instr. 3,			4 and Sec Ben Owi		curities neficially		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount		(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				(
Common stock, \$0.01 par value 05/09/						4			A ⁽¹⁾		2,764 A		\$0	13,858			D					
		Та	ble II - C								sed of, onvertib				y Ov	vned						
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) if any (Month/Day) (Month/Day) (Month/Day)				Date,	4. Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration				7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amour or Numbe of			ice of vative urity r. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		0. ovmership orm: oirect (D) r Indirect) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

1. These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

> Steven L. Scrogham, attorneyin-fact for Robert J. Alpern ** Signature of Reporting Person

05/13/2014

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.